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METHODS: All subjects possessing an influenza diagno-
sis (ICD-9-CM  487) in PharMetrics’ Integrated Out-
comes Database between January 1, 1997 and June 30,
1998 were eligible for inclusion. Subjects with an influenza
diagnosis one-year prior to their index date and subjects
with less than 3 months of data available for analysis prior
to or following first diagnosis were excluded. Comorbidi-
ties, influenza vaccinations, antiviral and antibiotic pre-
scriptions were also identified during the study period.
RESULTS: A total of 18,000 subjects met all inclusion
criteria. The mean age of all subjects was 29.1 years (Std
Dev  20.7). Inpatient costs accounted for over 35% of
the $12.8 million in total costs incurred during the study
period, even though only 3% (472) of the sample required
hospitalization for influenza. The mean cost of an influ-
enza related hospitalization was $9,667 (Std Dev 
20,940) per subject hospitalized. Antibiotics were pre-
scribed in approximately 28% of the subjects, however an-
tivirals were prescribed to only (7%) of the subjects.
CONCLUSIONS: Although hospitalization for influenza
was rare (3%), the costs associated with this outcome
were significant. Prevention of hospitalizations related to
influenza could result in significant cost savings for man-
aged care organizations.
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COST-EFFECTIVENESS OF PARTNER 
PHARMACOTHERAPY IN SCREENING FOR 
CHLAMYDIA TRACHOMATIS
Postma MJ1, Welte R2, Van den Hoek JAR3, Countinbo RA3, 
Jager JC2
1Groningen University Institute for Drug Exploration (GUIDE), 
Groningen, The Netherlands; 2National Institute for Public 
Health and the Environment, Bilthoven, The Netherlands; 
3Municipal Health Service, Amsterdam, The Netherlands
OBJECTIVE: To assess the cost-effectiveness of pharma-
cotherapy for partners in a screening program for asymp-
tomatic infection with Chlamydia trachomatis (CT) in
women.
METHODS: A decision-analysis model was constructed
for the health outcomes of a CT screening program, such as
averted cases of pelvic inflammatory disease and infertility
(major outcomes). Prevalence estimates of CT-infection
and information on partner referral were derived from pi-
lot studies in Amsterdam (the Netherlands). Reinfection
due to failed partner referral or non-compliance with part-
ner pharmacotherapy was included in the model. Cost-
effectiveness from a societal perspective was estimated for a
screening program in General Practices in Amsterdam, di-
rected at women aged 15–29. For diagnosis of asymptom-
atic CT infection a Ligase Chain Reaction test on urine was
used, for pharmacotherapy of women and partners azithro-
mycin was used. By linking health outcomes with health-
care costs and productivity losses averted costs were esti-
mated. Cost-effectiveness was expressed as net costs per
major outcome averted and was calculated in the reference
case and in sensitivity analysis.
RESULTS: Partner pharmacotherapy induces reductions
of approximately 50% in net costs per major outcome
averted of the screening program. Within the broader
framework of the screening program partner pharmaco-
therapy is a cost-saving activity.
CONCLUSIONS: Inclusion of partner pharmacotherapy
provides significant improvements in overall cost-effective-
ness of the CT-screening program. Partner pharmacother-
apy lowers net costs per major outcome averted to realms
where implementation of the screening program for women
aged 15-29 should be considered. Implementation of the
program is currently discussed for the city of Amsterdam.
Given the cost-saving potentials, male partner pharmaco-
therapy should be pursued within broader framework of a
CT-screening program for women.
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The economic impact of administration of the extremely
expensive new amphotericin B (Amph B) preparations is
huge for Greek hospitals.
OBJECTIVE: The purpose of this study is to present the
cost of amphotericin B therapy and the cost-efficacy results,
after administration, of the three amphotericin prepara-
tions, available in the Greek market, in a third-grade univer-
sity hospital.
METHOD: 88 amphotericin prescriptions dispensed by
the Hospital Pharmacy were monitored over 2 months.
RESULTS:
1. The three preparations available in the hospital Phar-
macy are: A. Classic Amph B (Fungisone); B. Liposo-
mal Amph B (Am Bisome); C. Lipid-complexed Amph
B (ABLC). These are offered at the following prices (in
USD): A: 100 mg  1D, B: 100 mg  336D, C: 100
mg  106D
2. Duration of Amph B therapy: 18  3 days
3. Number of flacons per patient per day: Adults 5–12 fl;
Children: 5  1
4. Departments of major administration: Intensive Care
Units (Surgical-AIDS-Internal Medicine), Nephrology,
Pediatrics, Unit of Peritoneal Clearance
5. Cost of therapy: a. Costs per day, per patient A: 3D, B:
1680–3360D, C: 530–1060D. b. Costs of Total Ther-
apy per patient: A 30D, B 54.000  4.000 D. C.:
14.400  2.600 D
6. No clinical evidence has been provided yet, whether ad-
ministration of liposomal or lipid-complexed Amph B is
cost-effective and the optimum necessary dosage.
CONCLUSION: Extremely high costs for Amph B ther-
apy become a threat for Social Insurance, because hospi-
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tal fees will necessarily increase tremendously; proven ef-
ficacy for these costs has not been provided in Greece yet.
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OBJECTIVES: To assess treatment patterns and treat-
ment-related costs of acute otitis media (AOM) in a Man-
aged Care population.
METHODS: All subjects diagnosed with AOM in Phar-
Metrics’ Integrated Outcomes Database between January
1, 1997 and December 31, 1998 were eligible for inclu-
sion. Subjects were classified as: AOM with major surgery,
AOM with minor surgery, or AOM with no surgery. Sub-
ject demographics, AOM—related utilization and costs,
and antibiotic prescriptions were measured during the
study period.
RESULTS: 322,626 subjects were included in the study,
with 97% falling into the AOM with no surgery category.
Approximately 50% of the subjects were 6 years of age or
older, while 52% of the subjects were female. The total
cost of treating AOM for these subjects was $76 million.
Minor and major surgery for AOM was more prevalent in
children aged 6 or older than any other age group, and
was associated with substantially higher costs. In 1997,
the mean cost for subjects undergoing major surgery was
$4,114 (std dev  3,290) compared to $142 (std dev 
335) for subjects not requiring surgery. The most com-
monly prescribed antibiotic overall was amoxicillin, fol-
lowed by sulfamethoxazole/trimethoprim; however, pre-
scribing patterns differed across AOM categories and age
groups.
CONCLUSIONS: Acute Otitis Media is a prevalent con-
dition associated with significant medical costs.
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OUTCOMES RESEARCH IN HEALTHCARE 
DECISION-MAKING AND 
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OBJECTIVES: To use routine data to study outcomes of
all knee and hip joint replacements in an unselected popu-
lation with universal coverage of healthcare.
METHODS: The study population was all resident in Tay-
side, Scotland from 1989–1995. Joint replacements, and
subsequent hospitalizations were identified from a hospital
discharge database. Death was recorded from a community
health database. The electronic records were validated
against primary case records for a random sample.
RESULTS: We identified 1,649 people who had first pri-
mary hip replacement and 989 first primary knee replace-
ments. Case note validation was performed for 274 pa-
tients, of whom 143 had no previous record of hip or knee
surgery and 131 had previous surgery. The proportion of
valid cases was higher in the patients with no previous sur-
gery (98% vs 57%). The most common mis-classification
was revision arthroplasty as primary arthroplasty because
of incomplete recording of previous joint replacement.
There were 353 deaths in the hip implant cohort (21.4%)
and 187 deaths in the knee implant cohort (18.9%); 6.4%
of hip recipients and 5.5% of knee recipients died within the
first year of implant. Four percent of hip replacements were
for management of hip fracture and they had significantly
reduced survival compared to the remaining patients (deaths
at 60 days, 1.6% vs. 0.8%). Significantly more knee recipi-
ents than hip recipients required revision of the joint re-
placement (4.4% vs 2.4%, p  0.007). Although time to
hip implant revision varied with the year of first implant
(with 1990 recipients showing the shortest time to revision),
this effect did not occur among knee implant recipients.
CONCLUSIONS: This study demonstrates the suitability
of the Scottish Morbidity record for postmarket surveil-
lance of medical device implants. The electronic data come
from a stable population with universal medical coverage
and outcomes can be validated by review of primary case
records.
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OBJECTIVES: Research on quality of life (QoL) of pa-
tients cured in childhood from malignant tumors. Wide us-
age of the latest anti-tumor methods of treatment has led
to considerable growth of the number of recovered pa-
tients during the last years. Only in Moscow between
1978–97 2255 children with oncological diseases were
successfully cured, 278 (12,3%) who had retroperitoneal
malignant tumors. Among these children 191 were cured
from nefroblastoma, 66 – from neuroblastoma, 21 – from
adrenal tumors. Antitumor treatment deeply affects the
child’s organism, causing not only physical dysfunction,
but also dramatic psychological, emotional and social
changes in the patient’s life. QoL research of the people
who suffered from malignant tumors in childhood is a new
area in Russian children’s oncology.
